Search - tctmd.com

October 11, 2019

News Daily News

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

October 09, 2019

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

September 20, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2019

August 30, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

August 26, 2019

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Todd Neale

August 23, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

August 22, 2019

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

August 21, 2019

News Daily News

TAVR Bleeds Stand Apart From PCI-Related Events

August 06, 2019

News Daily News

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

August 05, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2019

July 31, 2019

News Daily News

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

July 23, 2019

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

July 03, 2019

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Todd Neale

June 26, 2019

News Daily News

Platelet Function and Genetic Testing to Guide P2Y12 Inhibitor Meds in PCI: Updated Consensus

June 13, 2019

News Daily News

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

May 20, 2019

Taking Ticagrelor? Frank, Proactive Patient Conversations are Needed to Help With Adherence

News Daily News

Taking Ticagrelor? Frank, Proactive Conversations are Needed to Help With Adherence

Yael L. Maxwell

May 17, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction